Investigation of plaque vulnerability: Identification of atherosclerotic plaque angiogenesis using Bevacizumab-800CW and optoacoustic imaging: a single center proof of concept study (CAROTID-OPTOLIGHT)
Completed
- Conditions
- atherosclerotic plaqueCarotid plaque1000318410003216
- Registration Number
- NL-OMON45786
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 15
Inclusion Criteria
1) Patients with significant and symptomatic carotid stenosis who are scheduled for carotid endarterectomy as decided by the Multi-Disciplinary Carotid Board
Exclusion Criteria
1) Medical or psychiatric condition that compromise the patient*s ability to give informed consent
2) Pregnant or lactating women
3) Significant renal (creatinine >110 µmol/L) dysfunction
4) History of iodine allergy or anaphylactic reactions to insect bites or medication or previous allergic reaction to bevacizumab
5) Presence or history of hyperthyroidism
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>- To investigate whether it*s feasible to detect the carotid arteries and<br /><br>carotid plaques using optoacoustic imaging with the MSOT Acuity Echo in<br /><br>patients with symptomatic carotid stenosis.<br /><br>- Pre-operative detection of atherosclerotic plaques in carotid stenosis with<br /><br>VEGF-targeted Bevacizumab-800CW using NIRF, to evaluate if upregulated VEGF<br /><br>within the atherosclerotic plaque can be detected non-invasively, in which<br /><br>duplex findings and patients history are considered the gold standard.</p><br>
- Secondary Outcome Measures
Name Time Method <p>- Presence of fluorescent signal when endarterectomy is performed.</p><br>